- The Myeloma Beacon - https://myelomabeacon.org -
BT-062
By: Melissa Cobleigh; Published: October 4, 2010 @ 10:23 pm | Comments Disabled
| Brand Name: | |
| Generic Name: | |
| Code Name: | BT-062 |
| Company: | Biotest |
| FDA Clinical Phase: | 1/2 |
Description:
BT-062 (news articles [1]) is a toxic drug bound to an antibody that helps deliver the treatment to myeloma and other cancer cells. When the compound enters a cancer cell, it releases the toxic drug that ultimately kills the cell. In a Phase 1 trial, BT-062 demonstrated an acceptable and manageable safety proļ¬le as well as evidence of clinical efficacy.
Clinical Trials:
For a list of clinical trials studying BT-062 for the treatment of multiple myeloma, see ClinicalTrials.gov [2].
Information about BT-062 also is available at the Biotest website [3].
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2010/10/04/bt-062/
URLs in this post:
[1] news articles: https://myelomabeacon.org/tag/bt-062/
[2] ClinicalTrials.gov: http://www.clinicaltrials.gov/ct2/results?term=BT062&recr=&rslt=&type=&cond=myeloma&intr=&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=
[3] website: http://www.biotest.de/ww/en/pub/biotherapeutics/bt___062/multiple_myeloma/biotherapeutic_agent_bt_062.cfm
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.